image
Healthcare - Medical - Devices - NASDAQ - US
$ 49.37
-1.1 %
$ 628 M
Market Cap
32.91
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IRMD stock under the worst case scenario is HIDDEN Compared to the current market price of 49.4 USD, IRadimed Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IRMD stock under the base case scenario is HIDDEN Compared to the current market price of 49.4 USD, IRadimed Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one IRMD stock under the best case scenario is HIDDEN Compared to the current market price of 49.4 USD, IRadimed Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IRMD

image
$64.0$64.0$62.0$62.0$60.0$60.0$58.0$58.0$56.0$56.0$54.0$54.0$52.0$52.0$50.0$50.0$48.0$48.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
73.2 M REVENUE
11.71%
22 M OPERATING INCOME
9.63%
19.2 M NET INCOME
11.87%
25.6 M OPERATING CASH FLOW
90.30%
-8.82 M INVESTING CASH FLOW
-10.11%
-14.3 M FINANCING CASH FLOW
-4.98%
19.4 M REVENUE
5.80%
5.8 M OPERATING INCOME
0.19%
5.15 M NET INCOME
1.93%
5.99 M OPERATING CASH FLOW
-34.32%
-3.06 M INVESTING CASH FLOW
23.80%
-2.42 M FINANCING CASH FLOW
-26.02%
Balance Sheet IRadimed Corporation
image
Current Assets 75.2 M
Cash & Short-Term Investments 52.2 M
Receivables 10.6 M
Other Current Assets 12.5 M
Non-Current Assets 23.1 M
Long-Term Investments 0
PP&E 17 M
Other Non-Current Assets 6.12 M
53.12 %10.74 %12.66 %17.25 %6.22 %Total Assets$98.3m
Current Liabilities 8.51 M
Accounts Payable 1.9 M
Short-Term Debt 153 K
Other Current Liabilities 6.46 M
Non-Current Liabilities 2.99 M
Long-Term Debt 1.42 K
Other Non-Current Liabilities 2.99 M
16.48 %56.16 %26.01 %Total Liabilities$11.5m
EFFICIENCY
Earnings Waterfall IRadimed Corporation
image
Revenue 73.2 M
Cost Of Revenue 16.9 M
Gross Profit 56.3 M
Operating Expenses 34.4 M
Operating Income 22 M
Other Expenses 2.73 M
Net Income 19.2 M
80m80m70m70m60m60m50m50m40m40m30m30m20m20m10m10m0073m(17m)56m(34m)22m(3m)19mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
76.94% GROSS MARGIN
76.94%
29.99% OPERATING MARGIN
29.99%
26.26% NET MARGIN
26.26%
22.15% ROE
22.15%
19.56% ROA
19.56%
19.34% ROIC
19.34%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis IRadimed Corporation
image
18m18m16m16m14m14m12m12m10m10m8m8m6m6m4m4m2m2m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 19.2 M
Depreciation & Amortization 818 K
Capital Expenditures -8.01 M
Stock-Based Compensation 2.52 M
Change in Working Capital 3.75 M
Others -281 K
Free Cash Flow 17.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets IRadimed Corporation
image
Wall Street analysts predict an average 1-year price target for IRMD of $60 , with forecasts ranging from a low of $60 to a high of $60 .
IRMD Lowest Price Target Wall Street Target
60 USD 21.53%
IRMD Average Price Target Wall Street Target
60 USD 21.53%
IRMD Highest Price Target Wall Street Target
60 USD 21.53%
Price
Max Price Target
Min Price Target
Average Price Target
656560605555505045454040May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.27% DIVIDEND YIELD
0.17 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
2.002.001.801.801.601.601.401.401.201.201.001.000.800.800.600.600.400.400.200.200.000.0011.050.170.150.150.631.930.151.200.170.0020222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership IRadimed Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
286 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
84.4 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference WINTER SPRINGS, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that it will participate in the 37 th Annual Roth Conference. globenewswire.com - 1 month ago
IRADIMED CORPORATION (IRMD) Q4 2024 Earnings Call Transcript IRADIMED CORPORATION (NASDAQ:IRMD ) Q4 2024 Earnings Conference Call February 13, 2025 11:00 AM ET Company Participants Roger Susi - Founder, President and CEO John Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Nelson Cox - Lake Street Capital Markets Operator Welcome to the IRADIMED CORPORATION Fourth Quarter of 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode. seekingalpha.com - 2 months ago
IRadimed (IRMD) Lags Q4 Earnings Estimates IRadimed (IRMD) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.39 per share a year ago. zacks.com - 2 months ago
IRADIMED CORPORATION to Hold Fourth Quarter of 2024, Full Year of 2024 Financial Results Conference Call on February 13, 2025 WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. globenewswire.com - 2 months ago
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging compatible medical devices, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2024. globenewswire.com - 3 months ago
iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, iRadimed (IRMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. zacks.com - 3 months ago
IRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare Conference WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. globenewswire.com - 4 months ago
Here's Why Momentum in iRadimed (IRMD) Should Keep going iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. zacks.com - 4 months ago
IRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025 WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), today announced it has been ranked 24th on Forbes' list of America's Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. globenewswire.com - 4 months ago
iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. zacks.com - 5 months ago
IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024 WINTER SPRINGS, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune's 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. globenewswire.com - 5 months ago
IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript IRADIMED CORPORATION. (NASDAQ:IRMD ) Q3 2024 Earnings Conference Call October 31, 2024 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH Capital Partners Operator Welcome to the IRadimed Corporation Third Quarter of 2024 Financial Results Conference Call. seekingalpha.com - 5 months ago
8. Profile Summary

IRadimed Corporation IRMD

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 628 M
Dividend Yield 0.27%
Description IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Contact 1025 Willa Springs Drive, Winter Springs, FL, 32708 https://www.iradimed.com
IPO Date July 16, 2014
Employees 160
Officers Mr. Randy Waddell Vice President of Worldwide Sales & Marketing Mr. Matt Garner Controller Mr. Jeff Chiprin Chief Commercial Officer Mr. John F. Glenn Chief Financial Officer & Corporate Secretary Mr. Chris Williamson Executive Vice President of Continuous Improvement & Information Technology Mr. Lynn Neuhardt Vice President of Research & Development Mr. Roger E. Susi Founder, Chairman, Chief Executive Officer & President